BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BI 3804379 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BI 3804379\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06575400-6933@assetmemo.bio
DTSTAMP:20261121T010146Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:BI 3804379: Phase 1 readout est. (NCT06575400)
DESCRIPTION:BI 3804379\, phase 1\, MASH / NASH.\nStudy: A Study to Test How
  Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Pa
 tients With Metabolic Dysfunction-associated Steatohepatitis (MASH)\nEstim
 ated primary completion: 2 February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bi-3804379#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06575400
URL:https://assetmemo.bio/drug/bi-3804379#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
